Equities

Towa Pharmaceutical Co Ltd

Towa Pharmaceutical Co Ltd

Actions
  • Price (USD)24.35
  • Today's Change0.00 / 0.00%
  • Shares traded26.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 17 2021 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments29,65024,25732,830
Total Receivables, Net71,65754,39250,748
Total Inventory101,07292,92772,701
Prepaid expenses------
Other current assets, total15,33911,41410,585
Total current assets217,718182,990166,864
Property, plant & equipment, net153,642127,00499,873
Goodwill, net32,56834,61339,064
Intangibles, net18,01818,33218,999
Long term investments1,2481,2831,071
Note receivable - long term------
Other long term assets1,7601,8221,940
Total assets430,653371,347332,097
LIABILITIES
Accounts payable30,18747,61732,503
Accrued expenses96117108
Notes payable/short-term debt3,1123,67749,335
Current portion long-term debt/capital leases10,1207,52712,172
Other current liabilities, total36,60319,59120,955
Total current liabilities80,11878,529115,073
Total long term debt189,124150,31479,194
Total debt202,356161,518140,701
Deferred income tax------
Minority interest------
Other liabilities, total5,5185,6105,661
Total liabilities274,760234,453199,928
SHAREHOLDERS EQUITY
Common stock4,7174,7174,717
Additional paid-in capital7,8387,8377,837
Retained earnings (accumulated deficit)134,452121,232122,131
Treasury stock - common(5606)(5608)(5608)
Unrealized gain (loss)191106113
Other equity, total14,3018,6102,979
Total equity155,893136,894132,169
Total liabilities & shareholders' equity430,653371,347332,097
Total common shares outstanding494949
Treasury shares - common primary issue2.302.292.29
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.